370 related articles for article (PubMed ID: 34824739)
1. Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin-Converting Enzyme 2 and SARS-CoV-2 Main Protease.
Oso BJ; Olaoye IF; Omeike SO
Arch Razi Inst; 2021; 76(3):453-459. PubMed ID: 34824739
[TBL] [Abstract][Full Text] [Related]
2. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
3. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry.
Zhang D; Hamdoun S; Chen R; Yang L; Ip CK; Qu Y; Li R; Jiang H; Yang Z; Chung SK; Liu L; Wong VKW
Pharmacol Res; 2021 Oct; 172():105820. PubMed ID: 34403732
[TBL] [Abstract][Full Text] [Related]
4. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
[TBL] [Abstract][Full Text] [Related]
5. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
Nandi S; Roy H; Gummadi A; Saxena AK
Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
Ohishi T; Hishiki T; Baig MS; Rajpoot S; Saqib U; Takasaki T; Hara Y
PLoS One; 2022; 17(7):e0271112. PubMed ID: 35830431
[TBL] [Abstract][Full Text] [Related]
7. Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein.
Eskandari V
J Mol Model; 2022 May; 28(6):153. PubMed ID: 35578055
[TBL] [Abstract][Full Text] [Related]
8. In silico screening of Allium cepa phytochemicals for their binding abilities to SARS and SARS-CoV-2 3C-like protease and COVID-19 human receptor ACE-2.
Bondhon TA; Fatima A; Jannat K; Hasan A; Jahan R; Nissapatorn V; Wiart C; Pereira ML; Rahmatullah M
Trop Biomed; 2021 Jun; 38(2):214-221. PubMed ID: 34172713
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic and therapeutic potential of selected immunomodulatory agents from Ayurveda against coronaviruses amidst the current formidable scenario: an
Trivedi A; Ahmad R; Siddiqui S; Misra A; Khan MA; Srivastava A; Ahamad T; Khan MF; Siddiqi Z; Afrin G; Gupta A; Upadhyay S; Husain I; Ahmad B; Mehrotra S; Kant S
J Biomol Struct Dyn; 2022; 40(20):9648-9700. PubMed ID: 34243689
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.
Adeoye AO; Oso BJ; Olaoye IF; Tijjani H; Adebayo AI
J Biomol Struct Dyn; 2021 Jul; 39(10):3469-3479. PubMed ID: 32375574
[TBL] [Abstract][Full Text] [Related]
11. ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors.
Padhi S; Masi M; Chourasia R; Rajashekar Y; Rai AK; Evidente A
Eur J Pharmacol; 2021 Jan; 890():173648. PubMed ID: 33069672
[TBL] [Abstract][Full Text] [Related]
12. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
[TBL] [Abstract][Full Text] [Related]
13. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.
Kwofie SK; Broni E; Asiedu SO; Kwarko GB; Dankwa B; Enninful KS; Tiburu EK; Wilson MD
Molecules; 2021 Jan; 26(2):. PubMed ID: 33466743
[TBL] [Abstract][Full Text] [Related]
14. In Silico Screening of Natural Products as Potential Inhibitors of SARS-CoV-2 Using Molecular Docking Simulation.
Hossain R; Sarkar C; Hassan SMH; Khan RA; Arman M; Ray P; Islam MT; Daştan SD; Sharifi-Rad J; Almarhoon ZM; Martorell M; Setzer WN; Calina D
Chin J Integr Med; 2022 Mar; 28(3):249-256. PubMed ID: 34913151
[TBL] [Abstract][Full Text] [Related]
15. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation.
Gorla US; Rao K; Kulandaivelu US; Alavala RR; Panda SP
Comb Chem High Throughput Screen; 2021; 24(6):879-890. PubMed ID: 32819226
[TBL] [Abstract][Full Text] [Related]
16. In-silico evaluation of natural alkaloids against the main protease and spike glycoprotein as potential therapeutic agents for SARS-CoV-2.
Shah M; Yamin R; Ahmad I; Wu G; Jahangir Z; Shamim A; Nawaz H; Nishan U; Ullah R; Ali EA; Sheheryar ; Chen K
PLoS One; 2024; 19(1):e0294769. PubMed ID: 38175855
[TBL] [Abstract][Full Text] [Related]
17. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
18. The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion.
Chen TH; Tsai MJ; Chang CS; Xu L; Fu YS; Weng CF
J Infect Public Health; 2023 Jan; 16(1):42-54. PubMed ID: 36470006
[TBL] [Abstract][Full Text] [Related]
19.
Sharma P; Joshi T; Joshi T; Mathpal S; Maiti P; Nand M; Chandra S; Tamta S
J Biomol Struct Dyn; 2023 Feb; 41(2):646-658. PubMed ID: 34854365
[TBL] [Abstract][Full Text] [Related]
20. Systematic virtual screening in search of SARS CoV-2 inhibitors against spike glycoprotein: pharmacophore screening, molecular docking, ADMET analysis and MD simulations.
Dhameliya TM; Nagar PR; Gajjar ND
Mol Divers; 2022 Oct; 26(5):2775-2792. PubMed ID: 35132518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
